Search clinical trials for: REGN475/SAR164877

Total 31 results

Regeneron Pharmaceuticals

Terminated

Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain

Back Pain

United States
Regeneron Pharmaceuticals

Terminated

Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

Abdominal Pain Upper

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects

Healthy

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

United States
Regeneron Pharmaceuticals

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Healthy Volunteers

New Zealand
Regeneron Pharmaceuticals

Withdrawn

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodyplasia Ossificans Progressiva (FOP) | Heterotopic Ossification (HO)
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

Healthy Volunteers

Belgium
Regeneron Pharmaceuticals

Withdrawn

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva (LUMINA-1)

Fibrodysplasia Ossificans Progressiva

United States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom
Regeneron Pharmaceuticals

Completed

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Conjunctivitis | Allergic Rhinitis

Canada
Regeneron Pharmaceuticals

Completed

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Conjunctivitis | Allergic Rhinitis

United States, Belgium, Canada, Denmark, Germany
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain

Sciatica

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Regeneron Pharmaceuticals

Completed

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Regeneron Pharmaceuticals
Sanofi

Withdrawn

A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

Osteoarthritis
Regeneron Pharmaceuticals

Completed

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee

Osteoarthritis of the Knee

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip (FACT LTS & OA)

Osteoarthritis of the Knee or Hip

United States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals

Completed

A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

Low Back Pain

United States, Poland, Canada, Hungary, Denmark, Estonia, Czechia
Regeneron Pharmaceuticals

Recruiting

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA)

Fibrodysplasia Ossificans Progressiva

Japan, United States, Korea, Republic of, Spain, France, Australia, United Kingdom, China, Poland, Malaysia, Italy, Finland, Hong Kong, South Africa, Chile, Brazil, Netherlands, Colombia
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Regeneron Pharmaceuticals

Terminated

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Regeneron Pharmaceuticals
Department of Health and Human Services

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (COMBINE-EGFR-1)

Advanced Solid Tumors

United States, Turkey
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA1)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Hungary, Spain, Germany, United Kingdom, Denmark, Lithuania, Romania, Russian Federation, South Africa, Ukraine
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Eli Lilly and Company

Completed

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

Osteoporosis

United States, Canada
Regeneron Pharmaceuticals

Available

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

Ebola Virus Disease
Regeneron Pharmaceuticals

Active, not recruiting

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss (COURAGE)

Obesity

United States

3

Subscribe